Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Design, Synthesis and Anticholinesterase Activity of Novel Benzylidenechroman-4-Ones Bearing Cyclic Amine Side Chain Publisher Pubmed



Pourshojaei Y1 ; Gouranourimi A1 ; Hekmat S1 ; Asadipour A2 ; Rahmaninezhad S1 ; Moradi A3 ; Nadri H3 ; Moghadam FH3 ; Emami S4 ; Foroumadi A2, 5 ; Shafiee A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medicinal Sciences, Tehran, 14176, Iran
  2. 2. Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medicinal Sciences, Kerman, Iran
  3. 3. Department of Medicinal Chemistry, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  4. 4. Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
  5. 5. Drug Design and Development Research Center, Tehran University of Medicinal Sciences, Tehran, Iran

Source: European Journal of Medicinal Chemistry Published:2015


Abstract

A series of 3-(4-(aminoalkoxy)benzylidene)-chroman-4-ones 7a-r were designed and synthesized as analogs of homoisoflavonoids which are well known natural products with diverse pharmacological properties related to Alzheimer's disease. The in vitro anti-cholinesterase activity of designed compounds 7a-r against AChE and BuChE, revealed that compounds bearing piperidinylethoxy residue showed potent activity against AChE at sub-micromolar level (IC50 values = 0.122-0.207 μM), more potent than reference drug tacrine. The structure-activity relationships study of piperidinylethoxy series demonstrated that the selectivity and physicochemical properties of compounds could be optimized by selection of a proper substituent on the C-7 position of chroman ring, while the high potency of the molecule against AChE was reserved. © 2015 Elsevier Masson SAS.